Keymed Biosciences Inc. (HKG:2162)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
45.00
+1.05 (2.39%)
Apr 24, 2025, 4:08 PM HKT
39.32%
Market Cap 12.11B
Revenue (ttm) 455.60M
Net Income (ttm) -548.31M
Shares Out 275.60M
EPS (ttm) -2.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,475,500
Average Volume 2,868,742
Open 43.60
Previous Close 43.95
Day's Range 43.00 - 46.20
52-Week Range 27.05 - 49.60
Beta -0.03
RSI 57.34
Earnings Date Mar 28, 2025

About Keymed Biosciences

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In additio... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 1,258
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2162
Full Company Profile

Financial Performance

In 2024, Keymed Biosciences's revenue was 428.12 million, an increase of 20.91% compared to the previous year's 354.10 million. Losses were -515.24 million, 43.4% more than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.